You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股受捧 藥明生物、金斯瑞及信達生物漲6%-8% 百濟神州破頂
美股三大指數昨晚反覆高收漲0.6%-1%。港股繼昨天整固後,今天再發力,恆指曾升335點高見21,667創半年高,現報21,568,回升236點或1.1%,總成交額732億元。此外,科指回升1.2%報4,614。 瑞銀看好內地醫療保健板塊今年復甦,醫藥股今天發力,尤其是獲瑞銀納爲行業首選之一的信達生物(01801.HK)三連升,股價高見41.25元創11個月高,現報40.6元,續升8%。金斯瑞生物(01548.HK)再度逼近上週所創逾四個月高位(28.05元),最高見28元,現報27.6元,回升7.4%。獲麥格理升級至「跑贏大市」及上調目標價升至80元的藍籌藥明生物(02269.HK)曾漲近9%高見73.3元,創逾四個月高,現報71.4元,回升5.9%,暫爲表現最好藍籌。 百濟神州(06160.HK)回升逾半成曾高見160.4元再創52周高。騰盛博藥-B(02137.HK)升5.6%報8.36元;開拓藥業(09939.HK)續彈4.1%報11.1元。康希諾生物(06185.HK)續彈近3%曾高見74.9元。歌禮-B(01672.HK)升逾3%曾高見4.74元。 藍籌中生製藥(01177.HK)及石藥(01093.HK)續升逾2%-3%。威高股份(01066.HK)升逾3%報13.42元。藥明康德(02359.HK)升逾2.5%曾高見98元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account